Individualized Obesity Pharmacotherapy

Phase 3 Completed 193 enrolled Mayo Clinic

RandomizedParallel-groupTriple-blindTreatment

Summary

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Timeline

Start: 2017-12-11
Primary completion: 2022-05-26
Completion: 2022-05-26

Outcome

Met primary endpoint

paper mean weight loss of 15.9% compared with 9.0% in the non-phenotype-guided group (difference -6.9% [95% CI -9.4% to -4.5%], P < 0.001) PMID 33759389 ↗

Publications

Acosta A, Camilleri M, Abu Dayyeh B, Calderon G, Gonzalez D, McRae A, Rossini W, Singh S, Burton D, Clark MM. Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Obesity (Silver Spring). 2021 Apr;29(4):662-671. doi: 10.1002/oby.23120.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	3 mg	Subcutaneous
Subject	Naltrexone/bupropion	Unknown	32 mg	Oral
Subject	Naltrexone/bupropion	Unknown	360 mg	Oral
Comparator	Phentermine	Small molecule	15 mg	Oral
Comparator	Phentermine	Small molecule	37.5 mg	Oral
Subject	Phentermine-Topiramate	Unknown	7.5 mg	Oral
Subject	Phentermine-Topiramate	Unknown	46 mg	Oral